May 21, 2020
ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer
Mar 09, 2020
Senzer Secures US Clinical Data Package for the Treatment of Chemotherapy Induced Adverse Events
Nov 07, 2019
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
May 01, 2019
MMJ International Holdings Announces MOU for Manufacturing of THC-CBD Derived Drugs
Feb 27, 2019
Breckenridge Announces Final Approval of its ANDA for Exemestane Tablets (Aromasin®)
Oct 24, 2018
Eisai and Oklahoma Health Care Authority Enter Value-Based Agreement for FYCOMPA
May 15, 2018
Therapix Biosciences Issues CEO's Letter to Shareholders
Jan 03, 2018
Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Dec 29, 2017
ANI Pharmaceuticals Acquires Four NDAs from AstraZeneca for $46.5 Million
Nov 14, 2017
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
Oct 17, 2017
Tamoxifen Citrate Market 2017-2022 Global Trends and Future Insights
Oct 11, 2017
Upsher-Smith Launches Generic Version Of Aromasin® (Exemestane) Tablets
Oct 05, 2017
Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin
Jun 02, 2017
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer